J. Beeslaar

发表

Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence

J. Absalon, John L. Perez, R. Isturiz, 2019, Human vaccines & immunotherapeutics.

Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.

J. Absalon, John L. Perez, P. Balmer, 2018, Vaccine.

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.

J. Absalon, John L. Perez, K. Jansen, 2016, Vaccine.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

John L. Perez, K. Jansen, H. Marshall, 2012, The Lancet. Infectious diseases.

Understanding immunogenicity assessments for meningococcal serogroup B vaccines

J. Findlow, P. Balmer, Amit Srivastava, 2020, Postgraduate medicine.

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

John L. Perez, K. Jansen, T. Vesikari, 2016, Journal of the Pediatric Infectious Diseases Society.

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

J. Absalon, John L. Perez, R. O'neill, 2020, Infectious Diseases and Therapy.

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

J. Absalon, John L. Perez, K. Jansen, 2017, The New England journal of medicine.

Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.

J. Maguire, John L. Perez, H. Marshall, 2022, The Lancet. Infectious diseases.

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

J. Absalon, John L. Perez, K. Jansen, 2019, Vaccine.

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

J. Maguire, J. Absalon, John L. Perez, 2022, Vaccine.

A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults

J. Maguire, John L. Perez, H. Czajka, 2021, Vaccine.

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.

John L. Perez, K. Jansen, H. Marshall, 2017, The Lancet. Infectious diseases.

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

J. Maguire, J. Absalon, John L. Perez, 2020, Infectious Diseases and Therapy.

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Robert E. O'Neill, Kathrin U. Jansen, Jacek Wysocki, 2015, Journal of the Pediatric Infectious Diseases Society.

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.

J. Maguire, J. Absalon, John L. Perez, 2021, Vaccine.

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine

J. Absalon, John L. Perez, K. Jansen, 2018, Expert review of vaccines.

1082Safety, Tolerability, and Immunogenicity of an Investigational Meningococcal Serogroup B Bivalent rLP2086 Vaccine in Healthy Adolescents Aged 11 to 18 Years in Three Phase 2, Randomized, Controlled Studies

John L. Perez, T. Vesikari, S. Harris, 2014 .

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.

J. Maguire, John L. Perez, K. Jansen, 2023, The Lancet. Infectious diseases.

Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.

P. Peyrani, P. Balmer, C. Burman, 2023, Vaccine.